March 24, 2014
Med BioGene Announces Regulatory Approval of GeneFx® Lung
March 07, 2014
Med BioGene Announces Publication of Data Demonstrating Independent Validation of GeneFx® Lung
January 09, 2014
Med BioGene Announces Dismissal of Litigation With Signal Genetics LLC and Respira Health LLC
November 29, 2013
Med BioGene Reports Financial Results for Q3 2013
November 05, 2013
Med BioGene Provides GeneFx® Lung Regulatory and Commercialization Update
Lung cancer is the leading cause of cancer death
Clinical staging alone is inadequate; better prognostic tools are urgently needed
Early-stage NSCLC patients are treated primarily by surgical removal of their tumours. Recent clinical trials have established that adjuvant chemotherapy, administered after tumour removal, significantly improves the survival of stage II patients, but does not significantly improve the survival of stage I patients.
As a result, the American Society of Clinical Oncology and National Comprehensive Cancer Network recommend adjuvant chemotherapy for stage II patients but not for stage I patients. However, 30% to 55% of stage I and II patients still die as a result of the disease, implying that patients diagnosed with the same stage of disease can have markedly different treatment responses and overall outcomes. Currently, tumor stage (determined by the size and location of the tumour and lymph node involvement) remains the strongest predictor of survival but fails to account for this difference in patient outcomes. A more accurate means of prognostication is needed to improve the selection of patients for adjuvant chemotherapy. GeneFx® Lung is expected to help address this critical unmet need.
© Copyright 2006 - Med BioGene Inc. - Legal Disclaimer